Product Description: N-Acetyl-D-mannosamine (ManNAc) is an oral active sialic acid precursor that can prevent hypertension by increasing sialylation of IgG, making it a promising candidate for cardiovascular disease research. Additionally, N-Acetyl-D-mannosamine can activate hypocretin (HCRT) gene expression in orexin neurons and improve neurodegeneration caused by aging, offering potential avenues for research in neurological disorders[1][2][3][4][5].
Applications: Neuroscience-Neuromodulation
Formula: C8H15NO6
References: [1]Revilla-Nuin B, et al. Transport of N-acetyl-D-mannosamine and N-acetyl-D-glucosamine in Escherichia coli K1: effect on capsular polysialic acid production. FEBS Lett. 2002 Jan 30;511(1-3):97-101./[2]Hayakawa K, et al. Reactivation of hyperglycemia-induced hypocretin (HCRT) gene silencing by N-acetyl-d-mannosamine in the orexin neurons derived from human iPS cells. Epigenetics. 2017 Sep;12(9):764-778./[3]Peng J, et al. Supplementation With the Sialic Acid Precursor N-Acetyl-D-Mannosamine Breaks the Link Between Obesity and Hypertension. Circulation. 2019 Dec 10;140(24):2005-2018./[4]Niethamer TK, et al. Oral monosaccharide therapies to reverse renal and muscle hyposialylation in a mouse model of GNE myopathy. Mol Genet Metab. 2012 Dec;107(4):748-55./[5]Taniguchi S, et al. Chronic administration of N-acetyl-D-mannosamine improves age-associated impairment of long-term potentiation in the senescence-accelerated mouse. Neurosci Lett. 2015 Jun 26;598:41-6.
CAS Number: 3615-17-6
Molecular Weight: 221.21
Compound Purity: 98.0
Research Area: Neurological Disease; Cardiovascular Disease
Solubility: H2O : 125 mg/mL (ultrasonic)
Target: Endogenous Metabolite
English
Deutsch
